시장보고서
상품코드
939918

세계의 모노클로널 항체 파트너링 조건과 합의(2014-2020년)

Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022

발행일: | 리서치사: Current Partnering, a division of Wildwood Ventures Limited | 페이지 정보: 영문 700+ Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 모노클로널 항체 관련 시장에서 기업 제휴 계약의 체결 동향과 조건에 대해 조사분석했으며, 최근 동향, 대표적인 거래의 개요, 활발한 사업자, 최근 제휴 거래 리스트 등에 관한 정보를 정리하여 전해드립니다.

목차

개요

제1장 서론

제2장 모노클로널 항체 관련 계약 동향

  • 서론
  • 과거 수년간의 제휴
  • 제휴 계약에 가장 활발한 사업자
  • 모노클로널 항체 파트너링 : 거래 유형별
  • 모노클로널 항체 파트너링 : 치료 분야별
  • 모노클로널 항체 파트너링의 거래조건
    • 거래 총액
    • 선금 지불액
    • 목표 달성 보장금
    • 로열티료율

제3장 주요 모노클로널 항체 관련 거래

  • 서론
  • 주요 거래 : 금액별

제4장 모노클로널 항체 관련 가장 활발한 사업자

  • 서론
  • 가장 활발한 사업자
  • 가장 활발한 사업자의 개요

제5장 모노클로널 항체 관련 계약 디렉토리

  • 서론
  • 계약 디렉토리

제6장 모노클로널 항체 관련 거래 : 기술 유형별

  • 모노클로널 항체
  • 키메라 mAb
  • 인간화 mAb
  • 인간 mAb
  • 마우스 mAb

제7장 제휴 리소스 센터

  • 온라인 제휴
  • 제휴 이벤트
  • 참고 문헌

부록

KSA 20.06.17

The Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 report provides comprehensive understanding and unprecedented access to the monoclonal antibodies partnering deals and agreements entered into by the worlds leading healthcare companies.

The Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest monoclonal antibody agreements announced in the healthcare sectors, covering:

  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb
  • Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
  • This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since Jan 2015, including financial terms where available, including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
  • The initial chapters of this report provide an orientation of monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2015, including details of average headline, upfront, milestone and royalty terms.
  • Chapter 3 provides a review of the leading monoclonal antibody deals since 2015. Deals are listed by headline value, signed by big pharma, most active monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
  • Chapter 5 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • Chapter 6 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2015. The chapter is organized by specific monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • In addition, a comprehensive appendix is provided organized by monoclonal antibody partnering company A-Z, deal type definitions and monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • The report also includes numerous tables and figures that illustrate the trends and activities in monoclonal antibody partnering and dealmaking since 2015.
  • In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of monoclonal antibody technologies and products.

Key benefits

Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 provides the reader with the following key benefits:

  • In-depth understanding of monoclonal antibodies deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to the structure of monoclonal antibodies agreements
  • Comprehensive access to over 1100 actual monoclonal antibodies deals entered into by the world's biopharma companies
  • Identify the leading monoclonal antibody partnering companies
  • Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

  • Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 is intended to provide the reader with an in- depth understanding and access to monoclonal antibodies trends and structure of deals entered into by leading companies worldwide.

Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 includes:

  • Trends in monoclonal antibodies dealmaking in the biopharma industry since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to over 1100 monoclonal antibodies deal records
  • The leading monoclonal antibodies deals by value since 2015
  • Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2015

In Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Monoclonal antibodies type
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 report provides comprehensive access to available deals and contract documents for over 1100 monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise monoclonal antibody rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 provides the reader with the following key benefits:

  • In-depth understanding of monoclonal antibodies deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to the structure of monoclonal antibodies agreements
  • Comprehensive access to over 1100 actual monoclonal antibodies deals entered into by the world's biopharma companies, together with real world clause examples
  • Full listing of monoclonal antibodies deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading monoclonal antibodies deals by value since 2015
  • Identify the most active monoclonal antibodies dealmakers since 2015
  • Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in monoclonal antibody dealmaking

  • 2.1. Introduction
  • 2.2. Monoclonal antibody partnering over the years
  • 2.3. Most active monoclonal antibody dealmakers
  • 2.4. Monoclonal antibody partnering by deal type
  • 2.5. Monoclonal antibody partnering by therapy area
  • 2.6. Deal terms for monoclonal antibody partnering
    • 2.6.1 Monoclonal antibody partnering headline values
    • 2.6.2 Monoclonal antibody deal upfront payments
    • 2.6.3 Monoclonal antibody deal milestone payments
    • 2.6.4 Monoclonal antibody royalty rates

Chapter 3 - Leading monoclonal antibody deals

  • 3.1. Introduction
  • 3.2. Top monoclonal antibody deals by value

Chapter 4 - Most active monoclonal antibody dealmakers

  • 4.1. Introduction
  • 4.2. Most active monoclonal antibody dealmakers
  • 4.3. Most active monoclonal antibody partnering company profiles

Chapter 5 - Monoclonal antibody contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Monoclonal antibody contracts dealmaking directory

Chapter 6 - Monoclonal antibody dealmaking by technology type

  • Monoclonal antibodies
  • Chimeric mAb
  • Humanized mAb
  • Human mAb
  • Murine mAb

Appendices

  • Appendix 1 - Monoclonal antibody deals by company A-Z
  • Appendix 2 - Monoclonal antibody deals by stage of development
  • Appendix 3 - Monoclonal antibody deals by deal type
  • Appendix 4 - Monoclonal antibody deals by therapy area
  • Appendix 5 - Deal type definitions
  • Appendix 6 - Further Reading

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Therapeutic antibody definitions
  • Figure 2: Monoclonal antibody partnering since 2015
  • Figure 3: Active monoclonal antibody dealmaking activity since 2015
  • Figure 4: Monoclonal antibody partnering by deal type since 2015
  • Figure 5: Monoclonal antibody partnering by disease type since 2015
  • Figure 6: Monoclonal antibody deals with a headline value
  • Figure 7: Monoclonal antibody deals with an upfront value
  • Figure 8: Monoclonal antibody deals with a milestone value
  • Figure 9: Monoclonal antibody deals with a royalty rate value
  • Figure 10: Top monoclonal antibody deals by value since 2015
  • Figure 11: Most active monoclonal antibody dealmakers since 2015
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제